Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence from a Randomized Controlled Trial
Price Subsidies, Diagnostic Tests, and Targeting of Malaria Treatment: Evidence from a Randomized Controlled Trial
复制标题
DOI：
10.1257/aer.20130267
复制
发表时间：
2015-02-01
影响因子：
10.7
通讯作者：
Schaner, Simone
中科院分区：
文献类型：
--
作者：
Cohen, Jessica;Dupas, Pascaline;Schaner, Simone
对传染病治疗不足和过度都是公害。但是，努力减少一个风险会增加另一个风险。使用丰富的实验数据在肯尼亚的家庭寻求治疗的行为，我们研究了这种权衡的影响，以补贴在零售药店出售的非处方救命抗疟药。我们表明，一个非常高的补贴（如一个正在考虑由国际社会）显着增加获得，但近一半的补贴药片给病人没有疟疾。我们研究了两种更好地针对补贴药物的方法：降低补贴水平，以及引入非处方快速疟疾检测。
Both under-and over-treatment of communicable diseases are public bads. But efforts to decrease one run the risk of increasing the other. Using rich experimental data on household treatment-seeking behavior in Kenya, we study the implications of this trade-off for subsidizing life-saving antimalarials sold over-the-counter at retail drug outlets. We show that a very high subsidy (such as the one under consideration by the international community) dramatically increases access, but nearly one-half of subsidized pills go to patients without malaria. We study two ways to better target subsidized drugs: reducing the subsidy level, and introducing rapid malaria tests over-the-counter.